Compare UCL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UCL | MDXH |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | Hong Kong | Belgium |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 41.1M |
| IPO Year | 2019 | 2021 |
| Metric | UCL | MDXH |
|---|---|---|
| Price | $1.03 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 13.5K | ★ 1.2M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.51 |
| 52 Week High | $4.19 | $5.33 |
| Indicator | UCL | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 12.05 |
| Support Level | N/A | N/A |
| Resistance Level | $1.19 | $3.78 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 12.57 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.